Mirum Pharmaceuticals reports Q2 EPS (52c), consensus (47c)
PremiumThe FlyMirum Pharmaceuticals reports Q2 EPS (52c), consensus (47c)
1M ago
Mirum Pharmaceuticals announces label expansion for Livmarli
Premium
The Fly
Mirum Pharmaceuticals announces label expansion for Livmarli
2M ago
Mirum Pharmaceuticals: EU approves LIVMARLI for patients with PFIC
Premium
The Fly
Mirum Pharmaceuticals: EU approves LIVMARLI for patients with PFIC
2M ago
Mirum Pharmaceuticals price target raised to $39 from $34 at Baird
PremiumThe FlyMirum Pharmaceuticals price target raised to $39 from $34 at Baird
3M ago
Mirum Pharmaceuticals price target raised to $39 from $31 at JPMorgan
Premium
The Fly
Mirum Pharmaceuticals price target raised to $39 from $31 at JPMorgan
3M ago
Mirum Pharmaceuticals price target raised to $57 from $53 at Morgan Stanley
Premium
The Fly
Mirum Pharmaceuticals price target raised to $57 from $53 at Morgan Stanley
3M ago
Mirum updates elevate volixibat to meaningful value-driver status, says Stifel
PremiumThe FlyMirum updates elevate volixibat to meaningful value-driver status, says Stifel
3M ago
Mirum jumps after announcing interim results from two studies of volixibat
Premium
The Fly
Mirum jumps after announcing interim results from two studies of volixibat
3M ago
Mirum Pharmaceuticals price target raised to $39 from $34 at Baird
Premium
The Fly
Mirum Pharmaceuticals price target raised to $39 from $34 at Baird
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100